Google to Allow Cannabis and CBD Ads in Some US Regions

Dec.27.2022
Google to Allow Cannabis and CBD Ads in Some US Regions
Google to allow some cannabis and CBD ads in select US regions starting next month.

Starting next month, Google will no longer prohibit the advertising of certain cannabis and CBD products in certain regions of the United States.


Last week, this internet giant announced that it will update its policies on "risky products and services, as well as healthcare and pharmaceuticals", to allow for marijuana advertisements in California, Colorado, and Puerto Rico.


Google announced that starting on January 20, 2023, FDA-approved medications containing cannabidiol as well as topical marijuana-based CBD products containing THC levels of 0.3% or less can be advertised within these jurisdictions.


Some formats, including YouTube bumper ads, will no longer meet the criteria for placement," the company said. "CBD will be removed from the list of unapproved drugs and supplements. Advertising for other CBD-based products, including supplements, food additives, and inhalers, will continue to be prohibited.


It is currently unclear why Google has restricted policy changes to these two states and one US territory, as marijuana and its derivatives, such as CBD, are legal at the federal level and these products are sold nationwide.


Furthermore, a drug called Epidiolex, primarily made from cannabis, has been approved by the federal government for the treatment of severe epilepsy seizures. This has raised questions about further regional restrictions.


Google is partnering with a company called LegitScript to verify the eligibility of cannabis-related products for advertising and allow for "instant" submission of applications.


In the United States, only externally applied CBD products that have been certified by LegitScript are allowed to be promoted on Google, according to the company. The certification process requires products seeking promotion to (1) provide samples for testing to ensure they comply with legal THC restrictions and (2) supply LegitScript with third-party analytical certificates.


Scott Roth, CEO of LegitScript, stated in a press release, "When people see the LegitScript seal on your product or website, they know that your operation is safe and transparent.


In an industry that still commonly faces issues with contaminated, substandard, or illegal products, it is more important than ever to give consumers confidence that the CBD products they purchase have undergone proper scrutiny," he said.


Advertisers certified by LegitScript and FDA-approved CBD drugs "must first be certified by Google before they can start advertising," according to a Google notification summarized by Search Engine Land. "From the date of publication of the form on January 20, 2023, advertisers may apply for certification from Google.


Google's shift could be beneficial to the marijuana industry, especially if it ultimately expands to cover all states and regions. For advocates, the policy change is also a symbolic victory and consistent with the evolving stance of other actors in the tech field on this issue.


In 2019, Google received criticism for announcing that its app store, Google Play, would prohibit marijuana products. However, it appears that the company has now relaxed this stance, as delivery services like Eaze can now be found on its app marketplace.


Apple has expedited the standardization of marijuana applications, having lifted a similar ban in 2021.


Meanwhile, Google co-founder Sergey Brin joked at a post-election meeting in 2016 about providing joints for employees.


In recent news regarding technology and marijuana, Twitter appears to have ended a federal partnership this month that provided users who searched certain drug-related keywords (including "marijuana") with recommendations for drug treatment. No such recommendations appeared for searches related to "alcohol.


In 2019, a Facebook executive discussed how the social media giant could use visual artificial intelligence to detect "policy-violating content," including advertisements promoting the sale of marijuana on the platform.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Russia has placed shares in four Japan Tobacco International businesses under temporary management, the first such move involving a major global tobacco manufacturer, according to Interfax. JTI held 35.8% of Russia's tobacco market by volume in the first nine months of 2026. While British American Tobacco and Imperial Brands have exited Russia, Philip Morris International continues operating there. As the market changes and diplomatic efforts continue, could international tobacco companies that left Russia eventually return?
Nov.06
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03